Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population
Introduction: FreeStyle Libre 2 system is a sensor-based flash-monitoring system that measures interstitial fluid glucose. The study aimed to compare cost of FreeStyle Libre 2 system and self monitoring of blood glucose (SMBG) in the type 2 diabetes mellitus (T2DM) population from the Spanish Health...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Instituto de Salud Carlos III (ISCIII) |
| Repositorio: | Repisalud |
| Idioma: | inglés |
| OAI Identifier: | oai:repisalud.isciii.es:20.500.12105/18331 |
| Acceso en línea: | http://hdl.handle.net/20.500.12105/18331 |
| Access Level: | acceso abierto |
| Palabra clave: | Cost Diabetes Flash FreeStyle libre Glucose monitoring Costes y análisis de costes Automonitorización de la glucemia Diabetes mellitus tipo 2 Población Insulina Humans Blood Glucose Self-Monitoring Blood Glucose Diabetes Mellitus, Type 2 Extracellular Fluid Cost Savings Spain Hypoglycemic Agents Hospitalization Insulins Hospitals |
| Sumario: | Introduction: FreeStyle Libre 2 system is a sensor-based flash-monitoring system that measures interstitial fluid glucose. The study aimed to compare cost of FreeStyle Libre 2 system and self monitoring of blood glucose (SMBG) in the type 2 diabetes mellitus (T2DM) population from the Spanish Health System perspective. Methods: On the basis of data collected from a literature review, the cost of glucose monitoring was modelled for patients with T2DM on a basal-bolus insulin regimen. The cost estimate included annual consumption for glucose monitoring (strips, lancets and sensors) and severe hypoglycaemic events (SHE) manage ment. A published rate of SHE (2.5 episodes/patient-year) was considered. A reduction of SHE (- 48.8%) associated with FreeStyle Libre 2 system, derived from the REPLACE trial, was applied. Hospital attendance for 20.5% of SHEs (with subsequent hospital ization in 16.0%) was applied. Consumption of strips and lancets was set at 6/day for SMBG (derived from national monitoring recommendations), and 0.2/day for FreeStyle Libre 2 sys tem users, with 26 FreeStyle Libre 2 sensors/ year. Unitary costs (€, year 2020 excluding VAT) were derived from literature (€0.28/strip; €0.09/ lancet; €3.09/daily FM sensor; €3804/hospital ized SHE; €1794/hospital-attended non-admit ted SHE; €389/community-attended SHE). Results: Costs were €2700 and €2120/year/pa tient using SMBG or FreeStyle Libre 2 system, respectively. For 1000 patients with T2DM using basal-bolus insulin, 1220 SHEs/year (with 48 hospitalizations) could be prevented and FreeSytle Libre 2 system could generate cost savings of up to €580,953/year versus SMBG (- 21.5%) Conclusion: FreeStyle Libre 2 system is a potential cost-saving strategy in patients with T2DM in Spain on a basal-bolus insulin regimen. |
|---|